NasdaqGS - Delayed Quote • USD
Bio-Techne Corporation (TECH)
At close: May 10 at 4:00 PM EDT
After hours: May 10 at 7:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 7 | 12 | 11 |
| Avg. Estimate | 0.5 | 0.45 | 1.78 | 2.04 |
| Low Estimate | 0.47 | 0.41 | 1.75 | 1.95 |
| High Estimate | 0.52 | 0.48 | 1.84 | 2.15 |
| Year Ago EPS | 0.55 | 0.41 | 1.99 | 1.78 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 8 | 11 | 10 |
| Avg. Estimate | 306.76M | 289.41M | 1.16B | 1.25B |
| Low Estimate | 300M | 286.4M | 1.15B | 1.24B |
| High Estimate | 311.1M | 294.1M | 1.16B | 1.26B |
| Year Ago Sales | 301.32M | -- | 1.14B | 1.16B |
| Sales Growth (year/est) | 1.80% | -- | 2.00% | 7.80% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 0.55 | 0.43 | 0.41 | 0.45 |
| EPS Actual | 0.55 | 0.41 | 0.4 | 0.48 |
| Difference | 0 | -0.02 | -0.01 | 0.03 |
| Surprise % | 0.00% | -4.70% | -2.40% | 6.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.5 | 0.45 | 1.78 | 2.04 |
| 7 Days Ago | 0.49 | 0.45 | 1.78 | 2.05 |
| 30 Days Ago | 0.5 | 0.46 | 1.76 | 2.03 |
| 60 Days Ago | 0.5 | 0.46 | 1.75 | 2.02 |
| 90 Days Ago | 0.5 | 0.46 | 1.75 | 2.02 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 2 | 2 | 8 | 6 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | 1 | 2 | 2 |
Growth Estimates
| CURRENCY IN USD | TECH | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -9.10% | -- | -- | 8.40% |
| Next Qtr. | 9.80% | -- | -- | 11.90% |
| Current Year | -10.60% | -- | -- | 5.60% |
| Next Year | 14.60% | -- | -- | 13.00% |
| Next 5 Years (per annum) | 5.56% | -- | -- | 11.05% |
| Past 5 Years (per annum) | 12.63% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Benchmark: Buy to Buy | 5/2/2024 |
| Maintains | Baird: Outperform to Outperform | 5/2/2024 |
| Maintains | Deutsche Bank: Buy to Buy | 4/18/2024 |
| Maintains | Stephens & Co.: Overweight to Overweight | 2/2/2024 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 2/2/2024 |
| Downgrade | Stifel: Buy to Hold | 2/2/2024 |
Related Tickers
LEGN Legend Biotech Corporation
43.24
-5.01%
PCVX Vaxcyte, Inc.
65.19
-0.58%
RVMD Revolution Medicines, Inc.
37.25
-0.53%
UTHR United Therapeutics Corporation
264.27
-0.67%
ROIV Roivant Sciences Ltd.
11.13
-1.07%
ALNY Alnylam Pharmaceuticals, Inc.
150.47
-0.59%
BGNE BeiGene, Ltd.
161.13
-4.45%
JAZZ Jazz Pharmaceuticals plc
109.63
-3.09%
ARGX argenx SE
374.63
-2.07%
GMAB Genmab A/S
28.84
+0.10%